What are the GMP requirements for drugs in Canada? Cover Part C Division 2 of the Food and Drug Regulations (C.02.001 to C.02.030), Health Canada's GMP guide GUI-0001, GMP inspections and ratings, and how Canadian GMP compares with US FDA cGMP (21 CFR 210/211).

Canadian drug GMP is set out in Part C, Division 2 of the Food and Drug Regulations, and it is enforced through the drug establishment licence (DEL) required by Division 1A. The regulation is short and outcome-based. Health Canada's GUI-0001 sets out how inspectors interpret it, and inspections end in a Compliant (C) or Non-Compliant (NC) rating, with each observation graded Risk 1, 2 or 3. US cGMP (21 CFR 210/211) covers the same ground but is more detailed in the rule text itself. The main differences are structural: Canada licenses the whole supply chain, keeps quality control and testing inside Canada, and relies on mutual recognition agreements (MRAs).

Approach: I read the full consolidated text of C.02.001 to C.02.030 and the related Division 1A licensing provisions, plus the 21 CFR 210/211 paragraphs cited below. GUI-0001, the inspection policies, the MRAs and FDA's inspection classifications are not in the datasets I can search, so those points come from official canada.ca and fda.gov search snippets only.

1. Part C, Division 2 (C.02.001 to C.02.030)

Scope and sale prohibitions

• C.02.001 is repealed ^[1].
• C.02.002 defines "specifications" as identity, potency and purity properties, test methods and tolerances. It also defines "medical gas" and "packaging material" ^[2].
• The Division does not apply to antimicrobial agents (environmental and device disinfectants) ^[3].
• For export-only drugs, the specifications of the destination country apply ^[4].
• No importer or distributor may sell a drug that was not fabricated, packaged/labelled, tested and stored (including during transport) in line with the Division ^[5]. The same rule applies to anyone selling a drug they handled themselves ^[6].
• Imported active ingredients need a person in Canada responsible for their sale, and the label must show importer and responsible-person details ^[7].
• Active ingredients used in fabrication must themselves meet the Division ^[8].

Section-by-section requirements

Section(s)	Requirement
C.02.004 Premises	Clean, sanitary, orderly operations; surfaces that can be cleaned; contamination prevented [9]
C.02.005 Equipment	Cleanable, prevents contamination, fit for intended use [10]
C.02.006 Personnel	Supervision by personnel with training the Minister considers satisfactory [11]
C.02.007 to C.02.008 Sanitation	Written sanitation program [12]; written health, hygiene and clothing rules; people with a communicable disease or open lesions excluded from exposed-drug areas [13]
C.02.009 to C.02.010 Raw material testing	Each lot tested against specifications before use; retest when properties may change; water may be used before tests are complete [14]. Testing before receipt is allowed only with vendor evidence and periodic full confirmatory testing; identity testing is always required on receipt [15]
C.02.011 to C.02.012 Manufacturing control	Written procedures, and each lot made in compliance with them [16]. A recall system and a self-inspection program, plus oversight of contract sites, unless the site is a DEL holder in Canada or a recognized building in an MRA country with batch certificates [17]
C.02.012.1 to C.02.015 Quality control	Quality assured across all activities [18]. The QC department must be on premises in Canada and independent of manufacturing and sales [19]. The QC head approves release, returned goods, materials and reprocessing [20]. QC also pre-approves methods, investigates complaints and takes corrective action, and uses a competent laboratory [21]
C.02.016 to C.02.017 Packaging material testing	Each lot examined or tested against written specifications [22]. Identity check and label check on receipt [23]
C.02.018 to C.02.019 Finished product testing	Each lot tested against written, QC-approved specifications before release [24]. Importers, distributors and packagers test in Canada after receipt, or before receipt with vendor certification plus identity testing; exemptions are listed below the table [25][26]
C.02.020 to C.02.024.1 Records	Master production documents, batch evidence, stability evidence and test results, kept on premises in Canada; building plans and personnel records [27]. Retention periods are below the table. API supply-chain documentation must carry each handler's DEL number, activity, expiry date and lot [28]
C.02.025 to C.02.026 Samples	Importers and distributors keep a sample of each packaged lot in Canada until 1 year after expiry. Fabricators keep raw material samples for 2 years after last use. API samples are kept on the same periods as API records [29]. Samples must be large enough to test against specifications [30]
C.02.027 to C.02.028 Stability	Establish the shelf life in the marketed package [31] and run a continuing stability program [32]
C.02.029 Sterile products	Separate enclosed areas, supervision by personnel trained in microbiology, and a method scientifically proven to ensure sterility [33]
C.02.030 Medical gases	Exempt from the sample and stability sections C.02.025, C.02.027 and C.02.028 [34]

Exemptions from in-Canada finished product testing (C.02.019)

• Drugs from recognized buildings in MRA countries, where the importer keeps batch certificates.
• Certain COVID-19 drugs.
• Short-life radiopharmaceuticals.
• Some autologous gene-modified cell products and adeno-associated virus (AAV) vector products.
• Listed non-prescription drugs from recognized countries or regions.

Record retention periods (C.02.021 to C.02.024)

• Dosage-form records: 1 year after expiry. API records: 3 years after full distribution if the API has a retest date, otherwise 1 year after expiry. Raw material and packaging test records: 5 years after last use ^[35].
• Sale records for recall ^[36] and complaint records ^[37] follow similar periods.
• Self-inspection and sanitation records: at least 3 years ^[38].

Linked licensing rules (Division 1A)

• No one may fabricate, package/label, import, test, distribute or wholesale a drug except under a DEL. APIs are carved out of the distribution and wholesale licensing requirement ^[39].
• "MRA country" and "recognized building" are defined in C.01A.001 ^[40]. Designated authorities are set by a published list under C.01A.019 ^[41].
• Licensees must notify Health Canada within 15 days of a GMP contravention that may affect quality, safety or efficacy ^[42].
• Changes to buildings, equipment or procedures need a notice and a 90-day review window ^[43].
• The Minister can suspend a DEL for contraventions. The Minister must first weigh compliance history and health risk, and give written notice and a chance to be heard ^[44].

2. GUI-0001 (from canada.ca search snippets)

• Status: GUI-0001 is Health Canada's GMP guide for drug products, dated July 1, 2020.
• Audience: fabricators, packagers/labellers, testers, distributors, importers and wholesalers.
• Structure: for each section, it gives the exact Division 2 text, then a rationale, then Health Canada's interpretation of what you must do to comply.
• PIC/S links: it draws on PIC/S material, for example PIC/S Annex 11 for computerized systems and the PIC/S data-integrity guidance. It also requires an ongoing certification program where a site is not overseen by a PIC/S Participating Authority.
• Related guides: there are separate guides for APIs (GUI-0104), sterile drugs (Annex 1, GUI-0119), Schedule C drugs (GUI-0026), selected non-prescription drugs (GUI-0066) and validation (GUI-0029). A biologics guide (GUI-0027) has been out for consultation.

3. GMP inspections and ratings in Canada (canada.ca snippets)

• Ratings: each inspection ends in an overall rating of C (Compliant) or NC (Non-Compliant).
• Observation grades: observations are confirmed in the Exit Notice and classified under GUI-0023:
  • Risk 1 (critical): likely non-compliant product or a health risk, and any fraud, misrepresentation or data falsification.
  • Risk 2 (major): may produce a drug that does not consistently meet its market authorization.
  • Risk 3 (other): any other departure from GMP.
• Enforcement: an NC outcome is handled under POL-0004, the GMP and DEL enforcement policy.
• Domestic inspection cycle (POL-0011):
  • sterile fabrication: every 2 years
  • non-sterile fabrication, primary packaging/labelling and testing: every 3 years
  • secondary packaging/labelling, importation, distribution and wholesale: every 4 years
  • more often where compliance risk is identified.
• Foreign sites: sites must be listed on the importer's DEL and shown to be GMP-compliant. Under GUI-0080, Health Canada can rely on trusted partners' inspections through paper-based review.
• Public results: inspection report cards with observations and ratings are published in the Drug and Health Product Inspections Database (DHPID).
• MRAs: Health Canada lists four drug GMP MRAs: Australia, Switzerland, EEA-EFTA, and the EU under CETA. There is also a separate Canada-UK arrangement recognizing each other's inspections outside their own territory. The US FDA is not among the MRA partners listed.

4. How Canada compares with US cGMP (21 CFR 210/211)

Topic	Canada (Division 2)	US (21 CFR 210/211)
Legal hook	Sale prohibitions (C.02.003) plus DEL licensing (C.01A.004)	Failure to comply makes the drug adulterated under FD&C Act 501(a)(2)(B) [45]; Part 210 sets minimum cGMP [46]
Who is covered	Fabricators, packagers/labellers, testers, importers, distributors and wholesalers, including APIs	Manufacture, processing, packing or holding; firms comply only with the operations they perform [47]. Phase 1 investigational drugs are exempt from Part 211 [48]
Quality unit	Independent QC department on premises in Canada (C.02.013)	Quality control unit approves or rejects materials, products and contract-made product, and reviews records [49]; approves procedures and specifications [50]
Personnel	"Training satisfactory to the Minister"; exclusion for disease or lesions	Continuing cGMP training by qualified individuals [51]; exclusion for illness or open lesions [52]
Premises and sterile	Three-line outcome rules (C.02.004, C.02.029)	Spelled out in the rule: defined areas, HEPA-filtered positive-pressure air and environmental monitoring for aseptic processing [53][54]; validation of aseptic and sterilization processes [55]; penicillin segregation [56]
Cleaning and computer systems	Sanitation program (C.02.007); computerized systems covered in GUI-0001 via PIC/S Annex 11	Detailed cleaning SOPs [57]; computer change controls, backups and validation in the rule itself [58]
Incoming materials	Full testing per lot, or vendor certification plus identity testing and periodic full confirmatory testing	At least one identity test [59]; the supplier's report of analysis may be accepted if its reliability is validated at intervals [60]
Release	QC head approves (C.02.014); each lot tested (C.02.018)	Lab conformance to final specifications before release [61]; QCU record review and investigation of discrepancies, extended to related batches [62]
Imports	Importer re-testing in Canada unless an MRA, recognized building or listed exemption applies (C.02.019)	No equivalent importer re-testing provision in the Part 211 sections I reviewed
Records	Kept in Canada; 1 year after expiry; raw material test records 5 years after last use	1 year after expiry, or 3 years for expiry-exempt OTC products [63]; at least annual product quality review [64]
Reserve samples	Packaged lot kept in Canada until 1 year after expiry; raw materials for 2 years after last use	At least twice the testing quantity, kept 1 year after expiry, with annual visual examination [65][66]; active ingredient reserves also kept [67]
Stability and expiry	Continuing stability program in the marketed package	Written statistical program [68]; expiry date required [69]
Complaints	QC investigation and record (C.02.015, C.02.023)	Written procedure including a check for adverse-experience reporting [70]; kept until the later of 1 year after expiry or 1 year after receipt [71]
Self-inspection and recall	Required in the regulation (C.02.012)	Management must be notified of investigations, recalls and FDA observations [72]
Inspection outcome	C/NC rating with Risk 1, 2 or 3 observations; possible DEL suspension	Form FDA 483 observations, with a voluntary response in about 15 business days; classified NAI, VAI or OAI, generally within 90 days. OAI accompanies a Warning Letter and can block application approvals and export certificates (fda.gov snippets)

The overall pattern:

• Canada writes the outcomes into law and puts the detail in GUI-0001.
• The US writes much of that detail into Part 211 itself.
• Canada's distinctive features are licensing every actor in the chain, a QC department and records based in Canada, importer re-testing, and MRA-based exemptions.

Sources:

• Health Canada: Good Manufacturing Practices
• GUI-0001
• GMP guidance documents
• GUI-0023 risk classification
• POL-0004
• POL-0011
• GMP inspection summary reports
• GUI-0080
• MRA background
• Canada-UK inspection recognition
• FDA inspection classifications
• FDA Pharmaceutical Inspections and Compliance